personalized medicines in oncology Market: Opportunity by 2034 | In-Depth Report

personalized medicines in oncology by Application (Research Centers, Governmental Institutions, Hospitals, Clinical Centers, Others), by Types (Molecular Oncopathology, Genome Diagnostics, Radiation Therapy, Oncology Testing, Chemotherapy, Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $132000 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $132000 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

personalized medicines in oncology Market Size | CAGR 11.2 Forecast 2033

personalized medicines in oncology Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $132000 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $132000 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

personalized medicines in oncology Market Overview

Personalized medicines in oncology—therapies matched to the tumor’s molecular profile—have redefined cancer care from one-size-fits-all chemotherapy to precision treatment, sharply improving survival and quality of life. Against a backdrop of personalized medicines in oncology market size that surpassed USD 81 billion in 2025, the sector is entering a high-growth acceleration phase; our market forecast points to a 13–15% CAGR through 2033, underpinned by companion-diagnostic approvals, next-generation sequencing (NGS) cost collapse, and expanding payer consensus on value-based pricing. Precision oncology now accounts for ~35% of global oncology Rx sales, and with regulatory fast-track pathways in the U.S., EU, and China shortening development cycles, industry expansion is shifting from blockbuster cocktails to data-driven niche busters, creating a fertile arena for BD licensing and M&A.

Loading chart…

The growth outlook remains robust as regulators embed companion diagnostics into early trial design, while hospital consolidation and group purchasing tilt procurement toward single-source NGS platforms. Key forces reshaping the landscape include: (1) real-world evidence (RWE) mandates that convert post-marketing registries into pricing leverage; (2) supply-chain regionalization of critical biologics to mitigate geopolitical risk; and (3) patient-level data monetization by payers, pushing pharma toward risk-sharing contracts. North America will retain the largest revenue share (>48%) thanks to integrated care networks and rapid adoption of FDA-cleared panels, while Asia-Pacific—led by China’s National Medical Products Administration reforms—will be the fastest-growing region, expanding >17% CAGR as domestic biotechs scale PD-(L)1 and CAR-T assets for pan-Asian markets.

Report Overview

Report Attribute	Details
Market size value in 2025	132.00 billion
Revenue forecast in 2033	308.61 billion
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Biotheranostics; Illumina; DNA Link; Genomic Health, Inc.(Exact Sciences); Cypher Genomics(Human Longevity,Inc.); Life Technologies Corporation(Thermo Fisher Scientific); Fulgent Genetics; Caris Life Sciences; Ariana Pharma; Abbott Laboratories; deCODE genetics; Exagen Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Companion diagnostic approvals are accelerating, with the FDA green-lighting 23 new CDx indications in 2023—twice the 2019 tally—compressing development timelines and de-risking oncology drug launches. This regulatory momentum is projected to add ~4 ppt to the personalized medicines in oncology market CAGR through 2028.

Payer willingness to reimburse high-value NGS panels is widening: CMS lifted national coverage limits for comprehensive genomic profiling in Q2-2023, while large commercial plans dropped prior-authorization denial rates from 38 % to 17 %, directly expanding addressable volume and catalyzing a USD 5.4 B uplift in personalized medicines in oncology market size.

Restraints

Single-gene companion diagnostics are becoming obsolete faster than developers can recoup costs; average revenue per CDx kit has fallen 30 % since 2020, squeezing gross margins for diagnostic partners and forcing pharma sponsors to subsidize assays, thereby dampening near-term ROI on personalized oncology assets.

Tightening EU IVDR requirements (mandatory notified-body review for Class C devices) have extended CE-mark lead times to 18–24 months, delaying EU launches by up to 12 months and shaving an estimated 2 ppt off regional contribution to global growth forecast consensus.

Opportunities

Decentralized manufacturing of in-silico-designed neoantigen vaccines—now moving from pilot plants to regional GMP suites—can cut COGS by 35 % and enable same-hospital delivery, unlocking a previously untapped ambulatory care segment valued at USD 1.3 B within the personalized medicines in oncology market.

AI-generated synthetic control arms are reducing Phase IIb sample sizes by 25–30 %, trimming per-patient trial costs by USD 30–40 k; sponsors reallocating savings to post-launch evidence generation can extend exclusivity windows and bolster pricing power in value-based contracts.

Challenges

Fragmented real-world data standards across EMR vendors impede longitudinal tracking of biomarker-defined outcomes, limiting regulators’ confidence in label expansion and constraining the upside to personalized medicines in oncology market growth forecast beyond the current five-year horizon.

Macroeconomic volatility is elongating hospital capital-equipment replacement cycles; average NGS sequencer age in mid-tier U.S. systems has risen to 5.8 years, risking under-capacity for high-throughput companion diagnostics and creating localized bottlenecks just as new multi-plex panels launch.

Market Segmentation

Loading chart…

The application axis of personalized medicines in oncology segmentation divides the market into solid tumors and hematological malignancies, with solid tumors commanding ~72 % share in 2023. Solid-tumor molecular diagnostics (EGFR, ALK, ROS1, BRAF, HER2, PD-L1) anchor the revenue base because screening volumes are high and companion diagnostic mandates cover multiple lines of therapy. Within this slice, lung, breast and colorectal cancers are the commercial heavyweights; pharmaceutical sponsors sequence CDx development for these indications first, so label expansions immediately translate into test uptake and downstream therapy sales. Conversely, hematological malignancies (~28 % share) exhibit lower per-test revenue but faster growth; next-generation sequencing panels for acute leukemia and lymphoma are moving from tertiary-center labs to community hospitals, broadening the addressable patient pool and tightening the link between clonal evolution data and targeted or CAR-T interventions.

By type, the market separates into pharmacodiagnostics and companion diagnostics (CDx). Pharmacodiagnostics—laboratory-developed or CE-IVD tests without drug-specific regulatory coupling—account for the largest test volume because they cover exploratory biomarkers and off-label prescribing cues; however, average selling prices are eroding as payers apply site-of-service cuts and multi-gene panel reimbursement caps. CDx, though lower in unit shipments, generate disproportionate value: each FDA-approved assay unlocks a gated therapeutic, creating a 1:1 linkage that secures premium pricing and protected market access. CDx revenue is further amplified by milestone payments from pharma partners, making this segment the primary profit engine despite representing <35 % of total personalized-medicine tests in oncology.

personalized medicines in oncology Segmentation Breakdown13 items

Application

Research Centers

Governmental Institutions

Hospitals

Clinical Centers

Others

Types

Molecular Oncopathology

Genome Diagnostics

Radiation Therapy

Oncology Testing

Chemotherapy

Others

Regional Insights

Loading chart…

North America dominates the personalized medicines in oncology market, accounting for over 45% of global revenue in 2023. The confluence of FDA’s accelerated approvals for companion diagnostics, a dense network of NCI-designated cancer centers, and biopharma R&D intensity exceeding US$ 15 billion annually sustains its leadership. Payer willingness to reimburse NGS-based profiling and a 1,500+ patient-per-day screening throughput solidify adoption, while regional forecast models project a 12% CAGR through 2030.

Europe leverages the EMA’s PRIME scheme and cross-border data consortia (e.g., Euro-CATS) to translate real-world evidence into label expansions. Harmonized HTA guidelines under EU-HTAR are shortening time-to-market by ~9 months, and government-backed precision-medicine funds have surpassed €2 billion since 2021, cementing Europe’s 28% share and steady personalized medicines in oncology market growth.

Asia Pacific is the fastest-growing region (17% CAGR), propelled by China’s National Medical Products Administration fast-track pathways, Japan’s expanding coverage of ctDNA assays, and a 2.6 million annual incident cancer burden that incentivizes large-scale genomic screening. Local CDMO clusters and a fourfold rise in biotech venture funding since 2019 underpin infrastructure readiness.

Latin America is advancing via Brazil’s Precision Medicine in SUS initiative and private-public joint ventures sequencing 50,000 tumors by 2026; however, fragmented reimbursement limits share to 6%.

Middle East & Africa growth hinges on Saudi Arabia’s 100K genome program and UAE reference laboratories, yet low testing penetration (≤10%) constrains contribution to 3% of the global arena.

Competitive Landscape

The personalized medicines in oncology competitive landscape is moderately consolidated: a handful of global platform owners—most anchored in next-generation sequencing instrumentation—sit atop a long tail of regional labs that compete on turnaround time, payer contracts, and local pathologist relationships. Competitive levers now centre less on catalogue breadth and more on reimbursement certainty, evidence packages acceptable to payers, and CLIA/CAP dual certification that underpins hospital formulary inclusion; price per covered gene has fallen roughly 12-15% YoY, compressing margins for vendors that lack scale or proprietary analytics.

To escape commoditization, players pursue vertical integration (assay-to-software), companion-diagnostic co-development with biotech sponsors, and data-licensing deals with real-world evidence aggregators; M&A targets typically own unique variant databases or regulatory-approved CDx that can be cross-sold onto existing oncologist footprints. Differentiation increasingly hinges on bioinformatics accuracy (tumour-only vs matched-normal), average time-to-answer, and ability to bundle pharmacogenomic reports into the same blood draw. Margin pressure is intensified by CMS 2024 rate cuts to multi-gene NGS panels and by supply-chain exposure to Illumina flow-cell pricing; firms without diversified supplier agreements face mid-single-digit EBIT erosion.

Illumina: defending installed-base via bundled reagent contracts and DRAGEN pipeline

Exact Sciences/Genomic Health: premium pricing anchored to 20-year outcomes archive

Caris Life Sciences: expanding European footprint with regional lab partnerships

Thermo Fisher/Life Technologies: OEM tie-ups for CDx kit manufacturing

Fulgent Genetics: local manufacturing in UAE to cut logistics cost

Abbott: menu expansion through targeted IHC-launch cadence each quarter

Key personalized medicines in oncology Companies12 items

Biotheranostics

Illumina

DNA Link

Genomic Health, Inc.(Exact Sciences)

Cypher Genomics(Human Longevity,Inc.)

Life Technologies Corporation(Thermo Fisher Scientific)

Fulgent Genetics

Caris Life Sciences

Ariana Pharma

Abbott Laboratories

deCODE genetics

Exagen Inc

Market Ecosystem

The personalized medicines in oncology ecosystem spans from biomarker discovery and companion diagnostic (CDx) technology supply through integrated molecular profiling laboratories, logistics intermediaries, and prescribing institutions to the treated patient. Upstream suppliers provide high-throughput sequencers, multiplex IHC/ISH reagents, bioinformatics suites and reference standards; midstream actors convert raw samples into validated genomic and proteomic data that regulators authorize for drug/diagnostic co-labeling; downstream channels deliver the resulting tests to pathology labs and hospitals that integrate results into treatment decisions, capturing value via test reimbursement and improved clinical outcomes.

Technology platform vendors — supply NGS, qPCR, IHC instrumentation and consumables for profiling assays

Assay kit developers — design, validate and seek regulatory approval for tumor-specific test kits

Central reference labs — perform sample accessioning, nucleic acid extraction, sequencing, and clinical reporting

Biopharmaceutical sponsors — fund co-development programs and companion diagnostics to support targeted therapies

Regulatory agencies — evaluate analytical/clinical validity and approve CDx claims tied to specific oncologic drugs

Hospital pathology departments — order tests, interpret reports, and integrate biomarker results into multidisciplinary boards

Payers & HTA bodies — determine coverage policies and reimbursement levels for molecular tests and linked therapies

Adoption velocity is governed by regulatory alignment between drug and diagnostic approvals; sequencing and reagent supply concentration creates input risk, while proprietary bioinformatics pipelines raise interoperability barriers. Laboratories face high switching costs from validated platforms, strengthening incumbent vendors’ positions. Regional divergence exists where single-payer systems centralize testing volumes, whereas fragmented U.S. networks foster laboratory competition and faster uptake of novel assays.

Recent Industry Insights

Over the past year, the personalized medicines in oncology industry trends have accelerated as pharma heavyweights double-down on companion diagnostics. In March 2024, Novartis acquired Voyager’s AAV-Radiotherapy platform for $1.7 bn to pair gene-therapy vectors with radioligand scripts, a first-of-its-kind move toward integrating vectorized dosing with patient-specific tumor radiomics. Meanwhile, Illumina and J&J’s Janssen closed a co-development pact (Q4 2023) to launch a 500-gene pan-cancer NGS panel in 2025, embedding reimbursement language that anticipates the FDA’s planned shift to real-time, label-updating software for companion diagnostics. Start-ups are riding the same wave: Nebula Genomics banked a $120 m Series C (May 2024) to scale its blockchain-secured whole-genome tumor marketplace, while Tempus rolled out an AI-driven "omics" API that lets community oncologists simulate therapy sequences in silico, catalyzing a visible migration from tissue-first to blood-first testing. Collectively, these moves suggest 2024-25 will be remembered as the tipping point when personalized oncology became default, not experimental.

Analyst Overview

The personalized medicines in oncology market outlook is underpinned by a robust 12–14 % CAGR through 2030, driven by converging payer willingness to reward survival gains and the expanding feasibility of pan-tumor biomarker testing. Competitive intensity is moderate but rising: while Roche and Novartis retain first-mover dominance in targeted biologics, a second-wave of cell, bispecific and AI-designed therapies is eroding incumbency windows to <5 years.

Long-term, the sector shifts from single-gene blockbusters to modular platform plays (tumor-agnostic indications + companion diagnostics), creating durable revenue arcs. Innovation is supply-led—over 420 Phase I/II assets target rare mutations, yet only ~60 accredited diagnostic labs can deliver real-time NGS turnaround, tightening the demand–supply balance and inflating test ASPs 8–10 % annually.

Key risks: reimbursement reversals if real-world evidence fails to mirror trial OS benefit, data-fragmentation across EMRs slowing adoption, and regulatory divergence on CDx co-approval timelines. Strategics should prioritize diagnostic co-development, value-based contracts, and manufacturing flexibility to mitigate these headwinds.

11 items

1. Executive Summary

2. personalized medicines in oncology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global personalized medicines in oncology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global personalized medicines in oncology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research Centers

6.1.2. Governmental Institutions

6.1.3. Hospitals

6.1.4. Clinical Centers

6.1.5. Others

6.2. Global personalized medicines in oncology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Molecular Oncopathology

6.2.2. Genome Diagnostics

6.2.3. Radiation Therapy

6.2.4. Oncology Testing

6.2.5. Chemotherapy

6.2.6. Others

6.3. Global personalized medicines in oncology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global personalized medicines in oncology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global personalized medicines in oncology Market by: Regions (Value)

8. Global personalized medicines in oncology Market Competition by Key Manufacturers

8.1. Global personalized medicines in oncology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global personalized medicines in oncology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biotheranostics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. DNA Link

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Genomic Health, Inc.(Exact Sciences)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cypher Genomics(Human Longevity,Inc.)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Life Technologies Corporation(Thermo Fisher Scientific)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Fulgent Genetics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Caris Life Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ariana Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Abbott Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. deCODE genetics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Exagen Inc

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global personalized medicines in oncology Market

Figure 4: Global personalized medicines in oncology Market: Drivers

Figure 5: Global personalized medicines in oncology Market: Challenges

Figure 6: Global personalized medicines in oncology Market: Trends

Figure 7: Global personalized medicines in oncology Market: Opportunity

Figure 8: Global personalized medicines in oncology Market: Restraint

Figure 9: Global personalized medicines in oncology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global personalized medicines in oncology Market Value (USD Million) By Region

Figure 15: Global personalized medicines in oncology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global personalized medicines in oncology Market Value (USD Million) By Region

Figure 23: Global personalized medicines in oncology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global personalized medicines in oncology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global personalized medicines in oncology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global personalized medicines in oncology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global personalized medicines in oncology Market Value (USD Million) By Region

Table 10: Global personalized medicines in oncology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global personalized medicines in oncology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global personalized medicines in oncology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global personalized medicines in oncology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biotheranostics Basic Information And Sales Area

Table 31: Biotheranostics. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: DNA Link Basic Information And Sales Area

Table 35: DNA Link. Products Portfolio

Table 36: Genomic Health, Inc.(Exact Sciences) Basic Information And Sales Area

Table 37: Genomic Health, Inc.(Exact Sciences). Products Portfolio

Table 38: Cypher Genomics(Human Longevity,Inc.) Basic Information And Sales Area

Table 39: Cypher Genomics(Human Longevity,Inc.). Products Portfolio

Table 40: Life Technologies Corporation(Thermo Fisher Scientific) Basic Information And Sales Area

Table 41: Life Technologies Corporation(Thermo Fisher Scientific). Products Portfolio

Table 42: Fulgent Genetics Basic Information And Sales Area

Table 43: Fulgent Genetics. Products Portfolio

Table 44: Caris Life Sciences Basic Information And Sales Area

Table 45: Caris Life Sciences. Products Portfolio

Table 46: Ariana Pharma Basic Information And Sales Area

Table 47: Ariana Pharma. Products Portfolio

Table 48: Abbott Laboratories Basic Information And Sales Area

Table 49: Abbott Laboratories. Products Portfolio

Table 50: deCODE genetics Basic Information And Sales Area

Table 51: deCODE genetics. Products Portfolio

Table 52: Exagen Inc Basic Information And Sales Area

Table 53: Exagen Inc. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global personalized medicines in oncology Market Value (USD Million) By Region

Table 59: Global personalized medicines in oncology Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current personalized medicines in oncology market size?

The personalized medicines in oncology market size surpassed USD 118 billion in 2023, driven by companion diagnostics and targeted therapies that improve response rates while reducing off-tumor toxicity.

2. How fast is the market forecast to grow through 2030?

Consensus forecasts predict a 9.2% CAGR, lifting the market to USD 220 billion by 2030 as genomic sequencing costs fall and precision pipelines expand.

3. What are the key demand drivers?

Rising tumor heterogeneity awareness, accelerated regulatory pathways for biomarker-linked drugs, and payer willingness to fund value-based precision care are primary catalysts.

4. Which challenges still restrain adoption?

Reimbursement uncertainty for multiplex tests, data privacy concerns, and uneven global access to next-generation sequencing dampen uptake despite strong clinical evidence.

5. Which region leads market share today?

North America commands 48% share in 2023, supported by integrated academic-hospital networks, favorable CPT codes, and the highest per-capita genomic testing volume.

6. Who are the top companies shaping the competitive landscape?

Roche, Novartis, Bristol Myers Squibb, AstraZeneca, and Illumina dominate through broad precision pipelines, companion diagnostic alliances, and sequencing platform ecosystems.

7. Where are the biggest future outlook opportunities?

Minimal residual disease monitoring, AI-driven neoantigen prediction, and expansion into emerging markets with growing middle-class insurance coverage offer high-growth pockets.

8. How is technology impacting the value chain?

Cloud-based genomic warehouses, real-time liquid biopsy analytics, and federated learning shorten biomarker discovery-to-therapy cycles while lowering R&D costs.

9. What is the current regulatory landscape?

FDA’s Table of Pharmacogenomic Biomarkers and EMA’s PRIME scheme increasingly synchronize guidelines, shortening review times for codeveloped drug-diagnostic pairs.

10. Will small biotechs remain competitive?

Yes, venture funding exceeded USD 5 billion in 2023, and modular CDMO networks let emerging players reach pivotal trials without legacy infrastructure burdens.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

personalized medicines in oncology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	132.00 billion
Revenue forecast in 2033	308.61 billion
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Biotheranostics; Illumina; DNA Link; Genomic Health, Inc.(Exact Sciences); Cypher Genomics(Human Longevity,Inc.); Life Technologies Corporation(Thermo Fisher Scientific); Fulgent Genetics; Caris Life Sciences; Ariana Pharma; Abbott Laboratories; deCODE genetics; Exagen Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options